Abstract
Here, we identify a panel of melanoma lines with non-V600E mutations in BRAF. These G469E- and D594G-mutated melanomas were found to exhibit constitutive levels of phospho-extracellular signal-regulated kinase (pERK) and low levels of phospho-mitogen-activated protein kinase/ERK kinase (pMEK) and were resistant to MEK inhibition. Upon treatment with the CRAF inhibitor sorafenib, these lines underwent apoptosis and associated with mitochondrial depolarization and relocalization of apoptosis-inducing factor, whereas the BRAF-V600E-mutated melanomas did not. Studies have shown low-activity mutants of BRAF (G469E/D594G) instead signal through CRAF. Unlike BRAF, CRAF directly regulates apoptosis through mitochondrial localization where it binds to Bcl-2 and phosphorylates BAD. The CRAF inhibitor sorafenib was found to induce a time-dependent reduction in both BAD phosphorylation and Bcl-2 expression in the D594G/G469E lines only. Knockdown of CRAF using a lentiviral shRNA suppressed both Bcl-2 expression and induced apoptosis in the D594G melanoma line but not in a V600E-mutated line. Finally, we showed in a series of xenograft studies that sorafenib was more potent at reducing the growth of tumors with the D594G mutation than those with the V600E mutation. In summary, we have identified a group of melanomas with low-activity BRAF mutations that are reliant upon CRAF-mediated survival activity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Chen J, Fujii K, Zhang L, Roberts T, Fu H . (2001). Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci USA 98: 7783–7788.
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417: 949–954.
Dhomen N, Marais R . (2007). New insight into BRAF mutations in cancer. Curr Opin Genet Dev 17: 31–39.
Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin JA et al. (2006). In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 66: 9483–9491.
Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R et al. (2006). Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 95: 581–586.
Garnett MJ, Rana S, Paterson H, Barford D, Marais R . (2005). Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 20: 963–969.
Gray-Schopfer V, Wellbrock C, Marais R . (2007). Melanoma biology and new targeted therapy. Nature 445: 851–857.
Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL et al. (2008). The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 14: 230–239.
Houben R, Vetter-Kauczok CS, Ortmann S, Rapp UR, Broecker EB, Becker JC . (2008). Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. J Invest Dermatol 128: 2003–2012.
Jin S, Zhuo Y, Guo W, Field J . (2005). p21-activated Kinase 1 (Pak1)-dependent phosphorylation of Raf-1 regulates its mitochondrial localization, phosphorylation of BAD, and Bcl-2 association. J Biol Chem 280: 24698–24705.
Kyriakis JM, App H, Zhang XF, Banerjee P, Brautigan DL, Rapp UR et al. (1992). Raf-1 activates MAP kinase-kinase. Nature 358: 417–421.
O'Neill E, Rushworth L, Baccarini M, Kolch W . (2004). Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 306: 2267–2270.
Panka DJ, Wang W, Atkins MB, Mier JW . (2006). The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 66: 1611–1619.
Rapp UR, Rennefahrt U, Troppmair J . (2004). Bcl-2 proteins: master switches at the intersection of death signaling and the survival control by Raf kinases. Biochim Biophys Acta 1644: 149–158.
Smalley KS, Brafford P, Haass NK, Brandner JM, Brown E, Herlyn M . (2005). Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am J Pathol 166: 1541–1554.
Smalley KS, Contractor R, Haass NK, Kulp AN, Atilla-Gokcumen GE, Williams DS et al. (2007a). An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res 67: 209–217.
Smalley KS, Contractor R, Haass NK, Lee JT, Nathanson KL, Medina CA et al. (2007b). Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. Br J Cancer 96: 445–449.
Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M . (2006). Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5: 1136–1144.
Smalley KSM . (2003). A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 104: 527–532.
Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A et al. (2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 358–362.
Spittle C, Ward MR, Nathanson KL, Gimotty PA, Rappaport E, Brose MS et al. (2007). Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn 9: 464–471.
von Gise A, Lorenz P, Wellbrock C, Hemmings B, Berberich-Siebelt F, Rapp UR et al. (2001). Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals. Mol Cell Biol 21: 2324–2336.
Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM et al. (2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116: 855–867.
Wang HG, Rapp UR, Reed JC . (1996a). Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 87: 629–638.
Wang HG, Takayama S, Rapp UR, Reed JC . (1996b). Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. Proc Natl Acad Sci USA 93: 7063–7068.
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H et al. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099–7109.
Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ . (1996). Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87: 619–628.
Acknowledgements
We thank the Bayer Corporation for providing the BAY 43-9006 (sorafenib).
Author information
Authors and Affiliations
Corresponding authors
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
Supplementary information
Rights and permissions
About this article
Cite this article
Smalley, K., Xiao, M., Villanueva, J. et al. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 28, 85–94 (2009). https://doi.org/10.1038/onc.2008.362
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2008.362
Keywords
This article is cited by
-
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies
Nature Reviews Cancer (2024)
-
Targeting CRAF kinase in anti-cancer therapy: progress and opportunities
Molecular Cancer (2023)
-
Using molecular dynamics simulation to explore the binding of the three potent anticancer drugs sorafenib, streptozotocin, and sunitinib to functionalized carbon nanotubes
Journal of Molecular Modeling (2019)
-
Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
BMC Cancer (2018)
-
Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies
Nature Communications (2018)